Trial Profile
Reactogenicity and Safety of a Single Dose of GlaxoSmithKline Biologicals' Human Rotavirus (HRV) Vaccine (444563) in Healthy Children.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs RIX 4414 (Primary)
- Indications Rotavirus infections
- Focus Adverse reactions
- Sponsors GSK
- 04 May 2010 Actual patient number (51) added as reported by ClinicalTrials.gov.
- 04 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Mar 2010 New trial record